SCHEMBL21611985

SCHEMBL21611985

CC(C)Oc1ccc(-c2ccc(CNc3ccnc(C(F)(F)F)c3)nc2)cc1Cl

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CYP2C19 P33261 3/20 0.70
▸ CYP2C9 P11712 1/20 0.70
▸ KCNH2 Q12809 1/20 0.49
▸ KMO O15229 2/20 0.39
▸ CDK2 P24941 1/20 0.38
▸ GSK3B P49841 1/20 0.38
▸ CYP3A4 P08684 2/20 0.38
▸ S1PR1 P21453 4/20 0.36
▸ HDAC1 Q13547 3/20 0.36
▸ HDAC8 Q9BY41 3/20 0.36
▸ HDAC6 Q9UBN7 3/20 0.36
▸ PRMT6 Q96LA8 1/20 0.35
▸ PRMT1 Q99873 1/20 0.35
▸ PRMT8 Q9NR22 1/20 0.35
▸ P2RX3 P56373 1/20 0.35
▸ S1PR3 Q99500 1/20 0.35
▸ AAK1 Q2M2I8 1/20 0.35
▸ SMARCA2 P51531 1/20 0.34
▸ SMARCA4 P51532 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21614741 0.89 CYP2C19 (0.55) CYP2C19CYP2C9KCNH2KMOCDK2
SCHEMBL21614646 0.85 CYP2C19 (0.70) CYP2C19CYP2C9KCNH2KMOCDK2
SCHEMBL21612017 0.83 CYP2C19 (0.71) CYP2C19CYP2C9KCNH2KMOCDK2
SCHEMBL21612034 0.82 CYP2C19 (0.49) CYP2C19CYP2C9CDK2GSK3BCYP3A4
SCHEMBL23611253 0.82 CYP2C19 (0.49) CYP2C19CYP2C9KCNH2KMOS1PR1
SCHEMBL30060443 0.82 CYP2C19 (0.49) CYP2C19CYP2C9KCNH2KMOS1PR1
SCHEMBL21614655 0.81 CYP2C19 (0.48) CYP2C19CYP2C9CYP3A4HDAC1HDAC8
SCHEMBL21614733 0.80 CYP2C19 (0.46) CYP2C19CYP2C9CYP3A4HDAC1HDAC8
SCHEMBL23611440 0.80 CYP2C19 (0.47) CYP2C19CYP2C9KCNH2KMOS1PR1
SCHEMBL30062040 0.80 CYP2C19 (0.47) CYP2C19CYP2C9KCNH2KMOS1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210353606-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-11-18 — — US disclosed
EP-3818045-A1 PQSR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-05-12 — — EP disclosed
WO-2020007938-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-01-09 — — WO disclosed
WO-2020007938-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-01-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210353606-A1 PqsR INVERSE AGONISTS QRFPR, P2RY11, QARS1 CYP2C19 1824/4885CYP2C9 2997/4885KCNH2 2343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback